Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias (Q37715074)
Jump to navigation
Jump to search
scientific article published on 27 September 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias |
scientific article published on 27 September 2016 |
Statements
1 reference
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias (English)
1 reference
Hagop Kantarjian
1 reference
William Wierda
1 reference
Jorge Cortes
1 reference
Gautam Borthakur
1 reference
Farhad Ravandi
1 reference
Elias Jabbour
1 reference
Guillermo Garcia-Manero
1 reference
Marina Konopleva
1 reference
Michael Andreeff
1 reference
Naveen Pemmaraju
1 reference
Courtney D DiNardo
1 reference
Naval Daver
1 reference
Brittany Knick Ragon
1 reference
Zhihong Zeng
1 reference
Steven Kornblau
1 reference
Jan Burger
1 reference
LaKiesha DeBose
1 reference
Heather Schneider
1 reference
27 September 2016
1 reference
1 reference
7-11
1 reference
Identifiers
1 reference
1 reference
1 reference